Press Release: Garrett Motion Announces $250 Million Share Repurchase Program For 2026

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 6 through Nov. 12, 2025. Source: VerityData

Activist Filings

Pacira BioSciences (PCRX) Doma Perpetual Capital Management raised its stake in the pain-management biopharmaceutical company to 2,936,794 shares. Doma did so through the purchase of 238,176 Pacira BioSciences shares from Sept. 10 through Oct. 7 at prices ranging from $23.77 to $26.50, on average. On Nov. 10, Doma issued an open letter to Pacira's board of directors, advocating for the company to hire bankers and conduct a formal sales process for the business. The letter cites "management's unrelenting underperformance, out-of-control spending, and lack of prudent financial control."

Following the latest purchases, Doma Perpetual Capital Management owns a 6.8% stake in Pacira BioSciences' outstanding stock. Shares of Pacira have gained roughly 31% in value in 2025.

Decreases in Holdings

Garrett Motion (GTX) Cyrus Capital Partners reduced its stake in the vehicle-parts maker to 14,104,901 shares. Cyrus Capital did so through the sale of 4,542,226 Garrett Motion shares from Oct. 16 through Nov. 5 at per share prices ranging from $12.27 to $17.54.

Following the latest sales, Cyrus Capital continues to own 7.3% of Garrett Motion's outstanding stock. Shares of Garrett Motion have gained roughly 94.2% in value since the beginning of this year.

Sionna Therapeutics (SION) RA Capital Management lowered its stake in the clinical-stage biopharmaceutical company to 10,071,712 shares. RA Capital Management did so through the sale of 373,610 Sionna Therapeutics shares from Oct. 24 through Oct. 28 at per share prices ranging from $39.50 to $39.81.

Following the latest sales, RA Capital Management continues to own 22.6% of Sionna Therapeutics' outstanding stock. Shares of Sionna Therapeutics have gained roughly 45.1% in value in 2025.

Bitdeer Technologies Group (BTDR) Tether Holdings lowered its stake in the blockchain specialist to 30,356,531 shares. The cryptocurrency company sold 7,720,158 Bitdeer Technologies shares from Sept. 12 through Oct. 20 at per share prices ranging from $16.07 to $27.16.

Following the latest sales, Tether Holdings owns 14.3% of Bitdeer Technologies' outstanding stock. Shares of Bitdeer have lost approximately 39.4% of their value in 2025.

Concentrix (CNXC) Impactive Capital reduced its stake in the customer experience services provider to 3,066,213 shares. Impactive Capital did so through the sale of 1,308,912 Concentrix shares from Oct. 2 through Nov. 7 at per share prices ranging from $34.61 to $48.66.

Following the latest sales, Impactive Capital continues to own 4.9% of Concentrix's outstanding stock, placing Impactive below the 5% threshold that would require it to report further sales. Shares of Concentrix have lost roughly 18.8% of their value since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Oct. 30 through Nov. 5, 2025. Source: VerityData

Original Filings

MapLight Therapeutics (MPLT) Novo Holdings A/S disclosed a new position in the biopharmaceutical company of 3,686,622 shares. Novo purchased 952,941 of those shares into the company's initial public offering on Oct. 3 for $17 per share. Following those purchases, Novo owns an 8.4% stake in MapLight Therapeutics' outstanding stock. Shares of MapLight Therapeutics have lost roughly 12.8% of their value in 2025.

Increases in Holdings

Gold Royalty (GROY) Tether Holdings raised its stake in the gold-focused royalty company to 17,991,198 shares. Tether Holdings did so through the purchase of 9,691,198 Gold Royalty shares from Oct. 17 through Oct. 31 at per share prices ranging from $3.50 to $3.72. Following the latest purchases, Tether Holdings owns a 10.5% stake in Gold Royalty's outstanding stock. Shares of Gold Royalty have surged to gain 173.4% in value in 2025.

Neumora Therapeutics (NMRA) Arch Venture Partners raised its stake in the clinical-stage biopharmaceutical company to 33,958,967 shares. Arch Venture Partners did so through the purchase of 1,915,700 Neumora Therapeutics shares on Oct. 27 at a price of $2.61 per share. Following the latest purchases, Arch Venture Partners owns a 20.7% stake in Neumora Therapeutics' outstanding stock. Shares of Neumora Therapeutics have gained roughly 33% in value since the beginning of this year.

Decreases in Holdings

Insight Enterprises (NSIT) ValueAct Capital lowered its stake in the enterprise IT company to 1,666,739 shares. ValueAct did so through the sale of 435,000 Insight Enterprises shares from Oct. 10 through Oct. 28 at per share prices of $105.13 to $109.88. Following the latest sales, ValueAct continues to own 5.3% of Insight Enterprises' outstanding stock. Shares of Insight Enterprises have lost about 36.4% of their value in 2025.

Garrett Motion (GTX) Oaktree Value Opportunity Fund reduced its stake in the vehicle-parts maker to 25,894,816 shares. Oaktree did so through the sale of 6,000,000 Garrett Motion shares in a block sale to BofA Securities for $16.25 per share on Oct. 27. Following the latest sales, Oaktree Value Opportunity Fund continues to own 13.3% of Garrett Motion's outstanding stock. Shares of Garrett Motion have gained roughly 96% in value in 2025.

Rogers (ROG) Starboard Value lowered its stake in the engineered products company to 1,203,457 shares. Starboard Value did so through the sale of 473,045 Rogers shares from Oct. 24 through Oct. 31 at per share prices ranging from $83.42 to $86.92. Following the latest sales, Starboard Value continues to own 6.7% of Rogers' outstanding stock. Shares of Rogers have lost approximately 13.4% of their value in 2025.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

Strong margins and cash flow support investment in advanced technologies and share buybacks. Turbo and electrification platforms drive growth, with robust positions in Europe, China, and industrial markets. Variable cost structure and risk management underpin resilience.

Based on Garrett Motion Inc. [GTX] 49th Annual Automotive Symposium Audio Transcript — Nov. 3 2025